Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This trial will determine the feasibility and toxicity of dose intense (every 2 weeks) of
paclitaxel+carboplatin combination following cytoreductive surgery in patients with stage
Ic-IV ovarian cancer.